During the last session, Perspective Therapeutics Inc (AMEX:CATX)’s traded shares were 0.66 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stock’s price was $2.20, reflecting an intraday loss of -4.35% or -$0.1. The 52-week high for the CATX share is $19.05, that puts it down -765.91 from that peak though still a striking -0.91% loss since the share price plummeted to a 52-week low of $2.22. The company’s market capitalization is $162.91M, and the average intraday trading volume over the past 10 days was 0.61 million shares, and the average trade volume was 780.12K shares over the past three months.
Perspective Therapeutics Inc (CATX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.14. CATX has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.27.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Perspective Therapeutics Inc (CATX) registered a -4.35% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.35% in intraday trading to $2.20, hitting a weekly high. The stock’s 5-day price performance is -12.70%, and it has moved by -15.71% in 30 days. Based on these gigs, the overall price performance for the year is -82.26%. The short interest in Perspective Therapeutics Inc (AMEX:CATX) is 5.94 million shares and it means that shorts have 10.36 day(s) to cover.
The consensus price target of analysts on Wall Street is $21, which implies an increase of 89.52% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $22 respectively. As a result, CATX is trading at a discount of -900.0% off the target high and -809.09% off the low.
Perspective Therapeutics Inc (CATX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -51.45% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 153.17k as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 153.96k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 325k and 526k respectively. In this case, analysts expect current quarter sales to shrink by -52.87% and then drop by -70.73% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -9.86%. While earnings are projected to return -5.46% in 2025, the next five years will return -9.76% per annum.
CATX Dividends
Perspective Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-25. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Perspective Therapeutics Inc (AMEX:CATX)’s Major holders
Perspective Therapeutics Inc insiders own 18.63% of total outstanding shares while institutional holders control 64.35%, with the float percentage being 79.08%.
Also, the Mutual Funds coming in first place with the largest holdings of Perspective Therapeutics Inc (CATX) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.69 shares. This amounts to just over 2.51 percent of the company’s overall shares, with a $3.73 million market value. The same data shows that the other fund manager holds slightly less at 1.64, or about 2.43% of the stock, which is worth about $3.61 million.
